Regenerative focus Position Mogrify as a partner for regenerative medicine pipelines, highlighting their in vivo reprogramming platforms and collaboration model with pharma to accelerate development in ophthalmology, otology, metabolic and other degenerative diseases.

Strategic partnerships Target potential co-development or licensing deals with larger pharma players (e.g., Astellas) and biotech investors by emphasizing their proven funding traction, recent Series A growth, and ongoing collaborations to de-risk early-stage regenerative programs.

Preclinical translation Offer services or joint programs focused on translating in vivo reprogramming therapies from bench to preclinical stages, leveraging their platform to generate functional cell types and enable rapid target validation for high-need indications.

Data driven IP Leverage Mogrify’s big-data, transcription factor and growth factor prediction capabilities as a value proposition for partners seeking to de-risk cell fate engineering, with potential for tech licensing or sponsored research leveraging epiMOGRIFY and MOGRIFY platforms.

Geographic and domain expansion Explore opportunities in Cambridge and broader UK/EU life sciences clusters, presenting access to world-class researchers and multi-national collaborations to expand the addressable market, including ophthalmology and hearing loss therapy areas with unmet clinical needs.